HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥LungMate-014: Neoadjuvant Toripalimab Plus Chemotherapy With or Without Tifcemalimab (Anti-BTLA Antibody) in Potentially Resectable Stage III Non-Small Cell Lung Cancer: A Randomized, Phase II Trial 🎙️Dr. Peng Zhang 🔢2574RO 🎯pCR 32.2% vs 25.4% (n=118); 24-Mo EFS 71.1% vs 66.0%, 24-Mo OS 83.0% vs 76.1% 🎯Greater Benefit in Non-Squamous and PD-L1 TPS<1% ☑️NCT05891080 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 2 · 2 赞 · 0 回复 · 0 转发
会议摘要
NCT05891080NCT05891080按 - **标题 / Title：** Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial 对上
- **标题 / Title：** Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial读摘要原文 →来源：HHorinouchi · x.com